by telrheum | Jun 24, 2024 | Biologic Therapy, Anti-TNF, IL-23 Inhibitors, Il-6 inhibitors, JAK Inhibitor, Rituximab
Background: Rheumatoid arthritis (RA) patients often face higher cardiovascular risks due to chronic inflammation. Biologic disease-modifying antirheumatic drugs (biologic drugs) help control this inflammation, especially in those who don’t respond well to...
by telrheum | May 19, 2024 | Il-6 inhibitors, Hepatitis B, Infections, JAK Inhibitor
This study, presented at ACR Convergence 2023 by Akhil Sood, Janice Lin, and Neha Shah from Stanford University, examines the risk of Hepatitis B virus (HBV) reactivation in patients with rheumatoid arthritis (RA) who are being treated with either JAK inhibitors or...
by telrheum | Apr 23, 2024 | Biologic Therapy, Il-6 inhibitors, Infections, JAK Inhibitor
This article, “Risk of Hepatitis B Virus Reactivation in Patients with Rheumatoid Arthritis Receiving JAK Inhibitor or IL-6 Inhibitor: A Systematic Review and Meta-Analysis” by Akhil Sood, Janice Lin, and Neha Shah from Stanford University, presents a study that looks...
